ATOS Shares Plunge 32% — Retail Investors Weigh In on the Reverse Stock Split
Stock Split Announcement: Atossa Therapeutics has combined its 15 shares of common stock into one new share following a reverse stock split approved by its Board of Directors, effective February 2, 2026.
FDA Orphan Drug Designation: The FDA granted Orphan Drug Designation to Atossa's drug, Z-endoxifen, for the treatment of Duchenne muscular dystrophy, which is a severe genetic disorder primarily affecting boys.
Stock Performance: Following the stock split, Atossa's shares fell by 32% on the first day of trading, reflecting ongoing concerns among investors about potential dilution and the company's overall performance.
Financial Position: As of the end of September, Atossa reported cash and cash equivalents totaling $51.8 million, despite experiencing a 54% decline in stock value over the past year.
Trade with 70% Backtested Accuracy
Analyst Views on VTI
No data
About the author
CapitalWatch Withdraws Money Laundering Allegations Against AppLovin Shareholder
Internal Review Findings: Capital Watch revealed that an internal review found insufficient independent verification processes related to the Court of Bordeaux's judgment, leading to erroneous associations with Hao Tang.
Retraction of Allegations: Capital Watch has formally retracted its claims of financial crimes against Hao Tang and other individuals, acknowledging inaccuracies in earlier reports regarding direct connections to alleged illicit activities.
Continued Analysis: Despite the retraction, Capital Watch maintains its stance on the complexity of AppLovin's financial structure and will continue to independently analyze public market data related to the firm.
Market Reaction: Following the retraction, shares of AppLovin experienced volatility, initially dropping but later gaining over 21% in the past year, reflecting mixed sentiment among investors.
ATOS Shares Plunge 32% — Retail Investors Weigh In on the Reverse Stock Split
Stock Split Announcement: Atossa Therapeutics has combined its 15 shares of common stock into one new share following a reverse stock split approved by its Board of Directors, effective February 2, 2026.
FDA Orphan Drug Designation: The FDA granted Orphan Drug Designation to Atossa's drug, Z-endoxifen, for the treatment of Duchenne muscular dystrophy, which is a severe genetic disorder primarily affecting boys.
Stock Performance: Following the stock split, Atossa's shares fell by 32% on the first day of trading, reflecting ongoing concerns among investors about potential dilution and the company's overall performance.
Financial Position: As of the end of September, Atossa reported cash and cash equivalents totaling $51.8 million, despite experiencing a 54% decline in stock value over the past year.
Tesla Skeptic Claims New FSD Subscription Model Indicates Tech Lacks Asset Value: Retail Investors Share Worries
Tesla's Subscription Model: Tesla is transitioning its full self-driving (FSD) technology to a subscription model, which has raised concerns among analysts regarding its valuation as an appreciating asset.
Pricing Strategy: The pricing decision for the FSD subscription is seen as a crucial step towards standardizing software offerings for vehicles over the next five years, despite the current small customer base.
Market Reaction: Following the announcement, Tesla's stock experienced a decline, with analysts expressing skepticism about the technology's current capabilities and its impact on future valuations.
Future Outlook: Elon Musk indicated that the subscription service would begin on February 14, and there are calls for Tesla to reduce subscription costs to attract more customers and increase adoption rates.
Fund Manager Raises Alarm Over Tesla's Declining Delivery Figures and Elevated P/E Ratio
Tesla's Q4 Deliveries: In the fourth quarter of 2025, Tesla reported 418,227 vehicle deliveries, reflecting a 16% decline from the same quarter in 2024 and falling short of Wall Street expectations.
Earnings Expectations: Analysts anticipate Tesla will report Q4 revenue of $24.80 billion, below the $25.71 billion reported in Q4 2024, with adjusted earnings per share expected to be $0.44, down from $0.73 in the previous year.
Concerns Over EV Sales: Gary Black from Future Fund LLC expressed concerns about Tesla's declining electric vehicle sales impacting the company's share price, noting that EVs constitute over 70% of Tesla's profits.
Stock Market Sentiment: Despite recent challenges, Tesla's stock has gained 11% over the past year, with retail sentiment remaining bearish, although trading volumes have normalized after a period of high activity.
What’s Causing the Decline in SMCI Stock Price Today?
Market Expectations: Analysts expect Super Micro Computer, Inc. to lead in the AI server market in the medium term, but there are concerns about limited visibility in improving profitability due to increased competition and higher input costs.
Stock Price Adjustment: Mizhuho lowered the price target for Super Micro from $45 to $31 while maintaining a 'Neutral' rating, following Goldman Sachs' initiation of coverage with a 'Sell' rating and a target of $26.
Recent Stock Performance: Shares of Super Micro fell nearly 7% after the downgrade, reflecting a bearish sentiment among retail traders despite a generally bullish outlook in the market.
Collaborations and Innovations: Super Micro is partnering with various technology firms to deliver AI-powered retail solutions, aiming to enhance scalability and productivity while improving profitability through advanced infrastructure.
RZLV Shares Drop 9% Even with Positive Revenue Forecast: Retail Investors Seize the Opportunity
Revenue Projections: Rezoive AI plans to exit 2026 with at least $500 million in annual recurring revenue, projecting significant growth driven by demand in retail, financial services, and payments.
2025 Performance: The company reported approximately $209 million in annual recurring revenue for 2025, marking its first profitable period and highlighting improvements in operational leverage.
Stock Market Reaction: Despite positive growth outlooks, Rezoive AI's stock traded over 9% lower, with retail sentiment remaining extremely bullish, indicating investor confidence in long-term potential.
Operational Expansion: Rezoive AI expanded its workforce to over 1,000 employees globally in 2025, serving more than 650 enterprise customers and handling over 51 billion API calls, showcasing its scaling capabilities.
CapitalWatch Withdraws Money Laundering Allegations Against AppLovin Shareholder
Internal Review Findings: Capital Watch revealed that an internal review found insufficient independent verification processes related to the Court of Bordeaux's judgment, leading to erroneous associations with Hao Tang.
Retraction of Allegations: Capital Watch has formally retracted its claims of financial crimes against Hao Tang and other individuals, acknowledging inaccuracies in earlier reports regarding direct connections to alleged illicit activities.
Continued Analysis: Despite the retraction, Capital Watch maintains its stance on the complexity of AppLovin's financial structure and will continue to independently analyze public market data related to the firm.
Market Reaction: Following the retraction, shares of AppLovin experienced volatility, initially dropping but later gaining over 21% in the past year, reflecting mixed sentiment among investors.
ATOS Shares Plunge 32% — Retail Investors Weigh In on the Reverse Stock Split
Stock Split Announcement: Atossa Therapeutics has combined its 15 shares of common stock into one new share following a reverse stock split approved by its Board of Directors, effective February 2, 2026.
FDA Orphan Drug Designation: The FDA granted Orphan Drug Designation to Atossa's drug, Z-endoxifen, for the treatment of Duchenne muscular dystrophy, which is a severe genetic disorder primarily affecting boys.
Stock Performance: Following the stock split, Atossa's shares fell by 32% on the first day of trading, reflecting ongoing concerns among investors about potential dilution and the company's overall performance.
Financial Position: As of the end of September, Atossa reported cash and cash equivalents totaling $51.8 million, despite experiencing a 54% decline in stock value over the past year.
Tesla Skeptic Claims New FSD Subscription Model Indicates Tech Lacks Asset Value: Retail Investors Share Worries
Tesla's Subscription Model: Tesla is transitioning its full self-driving (FSD) technology to a subscription model, which has raised concerns among analysts regarding its valuation as an appreciating asset.
Pricing Strategy: The pricing decision for the FSD subscription is seen as a crucial step towards standardizing software offerings for vehicles over the next five years, despite the current small customer base.
Market Reaction: Following the announcement, Tesla's stock experienced a decline, with analysts expressing skepticism about the technology's current capabilities and its impact on future valuations.
Future Outlook: Elon Musk indicated that the subscription service would begin on February 14, and there are calls for Tesla to reduce subscription costs to attract more customers and increase adoption rates.
Fund Manager Raises Alarm Over Tesla's Declining Delivery Figures and Elevated P/E Ratio
Tesla's Q4 Deliveries: In the fourth quarter of 2025, Tesla reported 418,227 vehicle deliveries, reflecting a 16% decline from the same quarter in 2024 and falling short of Wall Street expectations.
Earnings Expectations: Analysts anticipate Tesla will report Q4 revenue of $24.80 billion, below the $25.71 billion reported in Q4 2024, with adjusted earnings per share expected to be $0.44, down from $0.73 in the previous year.
Concerns Over EV Sales: Gary Black from Future Fund LLC expressed concerns about Tesla's declining electric vehicle sales impacting the company's share price, noting that EVs constitute over 70% of Tesla's profits.
Stock Market Sentiment: Despite recent challenges, Tesla's stock has gained 11% over the past year, with retail sentiment remaining bearish, although trading volumes have normalized after a period of high activity.
What’s Causing the Decline in SMCI Stock Price Today?
Market Expectations: Analysts expect Super Micro Computer, Inc. to lead in the AI server market in the medium term, but there are concerns about limited visibility in improving profitability due to increased competition and higher input costs.
Stock Price Adjustment: Mizhuho lowered the price target for Super Micro from $45 to $31 while maintaining a 'Neutral' rating, following Goldman Sachs' initiation of coverage with a 'Sell' rating and a target of $26.
Recent Stock Performance: Shares of Super Micro fell nearly 7% after the downgrade, reflecting a bearish sentiment among retail traders despite a generally bullish outlook in the market.
Collaborations and Innovations: Super Micro is partnering with various technology firms to deliver AI-powered retail solutions, aiming to enhance scalability and productivity while improving profitability through advanced infrastructure.
RZLV Shares Drop 9% Even with Positive Revenue Forecast: Retail Investors Seize the Opportunity
Revenue Projections: Rezoive AI plans to exit 2026 with at least $500 million in annual recurring revenue, projecting significant growth driven by demand in retail, financial services, and payments.
2025 Performance: The company reported approximately $209 million in annual recurring revenue for 2025, marking its first profitable period and highlighting improvements in operational leverage.
Stock Market Reaction: Despite positive growth outlooks, Rezoive AI's stock traded over 9% lower, with retail sentiment remaining extremely bullish, indicating investor confidence in long-term potential.
Operational Expansion: Rezoive AI expanded its workforce to over 1,000 employees globally in 2025, serving more than 650 enterprise customers and handling over 51 billion API calls, showcasing its scaling capabilities.
